falsefalse

New Treatment Options for DLBCL: Impact on Sequencing Therapeutic Choices - Episode 4

Tafasitamab and Lenalidomide for R/R DLBCL

, , , , ,

A comprehensive overview of tafasitamab plus lenalidomide for patients with relapsed/refractory DLBCL, highlighting data updates and the impact on clinical practice.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    x